A new report from IMARC Group entitled China Diabetes Market Outlook (2010-2015) expects the Chinese diabetes market to grow at a CAGR of 28% during 2011-2015 reaching revenues worth USD 2.8 Billion. The report gives a comprehensive insight into the Chinese diabetes market and serves as an excellent tool to understand not only the market trends, structure, drivers and restraints but also the outlook of the market till 2015. This report aims to serve as a statistical as well as an analytical guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into Chinese diabetes market in some form or the other.
In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.
Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.
Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.
Chinas Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.
The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.
Forecasts: The report provides forecasts on:
Number of diabetes patients
Diagnosis and treatment rates in China
Non-Insulin Anti-diabetics market
All other Non-Insulin Anti-diabetic classes
Competitive Landscape: This section covers:
2005-2009 sales and market shares of top players in the diabetes market
2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes
2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes
2005-2009 sales and market shares of top players in the Insulin market
2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market.
Key Questions Answered in this report
What is the total size of the diabetes population in China and what are its characteristics?
What are the diagnosis and drug treatment rates for diabetes in China?
What are the key factors driving the growth of diabetes medication in China?
What is the Size and Breakup of the total diabetes market in China?
What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China?
What is the Size and Breakup of the total Insulin market in China?
Who are the key players in the Chinese diabetes market and how have they performed?
What is the outlook of the Chinese diabetes market in the next five years?
Which new products are expected to be launched in the next five years?
Which therapy classes will show the highest growth in the next five years?
What are the road blocks in the Chinese diabetes market?
TABLE OF CONTENTS
2.DIABETES DISEASE OVERVIEW
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.3 DIABETES COMPLICATIONS
3.THE CHINESE DIABETES MARKET: WHY IS IT SO LUCRATIVE?
3.1 CHINA HAS ONE OF THE LARGEST DIABETES PATIENT POOLS IN THE WORLD.
3.2 CHINA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 INCREASING AFFORDABILITY OF HEALTHCARE
3.4 MORE THAN A BILLION DOLLARS WORTH OF MARKET REMAINS UNTAPPED
3.5 A BETTER IPR REGIME IS DRIVING THE LAUNCH NEW AND INNOVATIVE DRUGS
4.DRIVERS OF DIABETES IN CHINA
4.1 AGEING POPULATION
4.2 INCREASING OBESITY LEVELS
5.THE CHINESE DIABETES EPIDEMIOLOGY
5.1 TOTAL PREVALENCE
5.1.1 Urban and Rural Prevalence
5.1.2 Prevalence of Diabetes by Sex
5.1.3 Prevalence of Diabetes by Age Group
5.2 DIAGNOSIS AND TREATMENT RATES IN CHINA
6.THE CHINESE DIABETES MARKET
6.1 MARKET TREND (2005-2009)
6.2 MARKET SEGMENTATION (2005-2009)
6.3 MARKET FORECASTS (2010-2015)
7.THE CHINESE NON-INSULIN ANTI-DIABETICS MARKET
7.1 MARKET TREND (2005-2009)
7.2 COMPETITIVE LANDSCAPE (2005-2009)
7.3 MARKET FORECASTS (2010-2015)
7.4 MARKET SEGMENTATION (2005-2015)
7.4.1 Alpha-Glycosidase Inhibitors
188.8.131.52 Market Trend (2005-2009)
184.108.40.206 Competitive Landscape
220.127.116.11 Market Forecasts (2010-2015)
18.104.22.168 Market Trend (2005-2009)
22.214.171.124 Competitive Landscape
126.96.36.199 Market Forecasts (2010-2015)
188.8.131.52 Market Trend (2005-2009)
184.108.40.206 Competitive Landscape
220.127.116.11 Market Forecasts (2010-2015)
18.104.22.168 Market Trend (2005-2009)
22.214.171.124 Competitive Landscape
126.96.36.199 Market Forecasts (2010-2015)
188.8.131.52 Market Trend (2005-2009)
184.108.40.206 Competitive Landscape
220.127.116.11 Market Forecasts (2010-2015)
7.4.6 Dpp-IV Inhibitors
18.104.22.168 Competitive Landscape
22.214.171.124 Market Forecasts (2010-2015)
7.4.7 Glp-1 Agonists
126.96.36.199 Competitive Landscape
188.8.131.52 Market Forecasts (2010-2015)
7.4.8 All other Classes
184.108.40.206 Market Trend (2005-2009)
220.127.116.11 Competitive Landscape
18.104.22.168 Market Forecasts (2010-2015)
8.THE CHINESE INSULIN MARKET
8.1 MARKET TREND (2005-2009)
8.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
8.3 MARKET SEGMENTATION BY MODE OF ACTION
8.4 COMPETITIVE LANDSCAPE
8.4.1 Share of key Players
8.4.2 Insulin Portfolio of Key Players
8.5 MARKET FORECASTS (2005-2010)
9.1 MILLIONS DONT EVEN KNOW IF THEY HAVE DIABETES
9.2 DESPITE THE LARGE POPULATION BASE, AVERAGE SPENDING ON DIABETES REMAINS FAIRLY LOW
9.3 REGULATORY & BUREAUCRATIC HURDLES
9.4 LARGE FINANCIAL DISPARITY
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
IMARC Group North America
IMARC Group Europe, Middle East & Africa
To know more please visit: http://www.imarcgroup.com/china-diabetes-market-report-and-outlook-2010-2015/
For more information, visit: http://www.imarcgroup.com